Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
Phase 2 Suspended
77 enrolled
Testing Obeticholic Acid for Familial Adenomatous Polyposis
Phase 2 Suspended
80 enrolled
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
Phase 2 Suspended
33 enrolled
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
Phase 2 Suspended
60 enrolled
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
Phase 2 Suspended
80 enrolled
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
Phase 2 Suspended
7 enrolled
TOP 2301: Neoadjuvant Chemo for NSCLC
Phase 2 Suspended
126 enrolled
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
Phase 2 Suspended
75 enrolled
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Phase 2 Suspended
186 enrolled
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Phase 2 Suspended
9 enrolled
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
Phase 2 Suspended
39 enrolled
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
Phase 2 Suspended
16 enrolled
Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in Treating Patients With Recurrent Head and Neck Cancer
Phase 2 Suspended
68 enrolled
ARCITECT
Phase 2 Suspended
120 enrolled
Pembrolizumab in Neoplasms or Lymphomas
Phase 2 Suspended
18 enrolled 16 charts
ERASE-CRC
Phase 2 Suspended
477 enrolled
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Phase 2 Suspended
36 enrolled
Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
Phase 2 Suspended
20 enrolled
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Phase 2 Suspended
33 enrolled
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
Phase 2 Suspended
33 enrolled
Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca
Phase 2 Suspended
48 enrolled
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
Phase 2 Suspended
29 enrolled
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
Phase 2 Suspended
70 enrolled
Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer
Phase 2 Suspended
38 enrolled
IMPACT
Phase 2 Suspended
120 enrolled
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma
Phase 2 Suspended
123 enrolled
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)
Phase 2 Suspended
10 enrolled
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Phase 2 Suspended
84 enrolled
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
Phase 2 Suspended
90 enrolled
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
Phase 2 Suspended
140 enrolled
Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Phase 2 Suspended
10 enrolled
A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)
Phase 2 Suspended
1 enrolled
Lip-Re2
Phase 2 Suspended
16 enrolled
ICUREC
Phase 2 Suspended
31 enrolled
NEST-1
Phase 2 Suspended
36 enrolled
TORCH-G
Phase 2 Suspended
68 enrolled
Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)
Phase 2 Suspended
61 enrolled
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
Phase 2 Suspended
59 enrolled
RILUZOX-01
Phase 2 Suspended
80 enrolled
SIRIUS
Phase 2 Suspended
93 enrolled
EXCALIBUR3
Phase 2 Suspended
62 enrolled
SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma
Phase 2 Suspended
34 enrolled
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Phase 2 Suspended
29 enrolled
A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG
Phase 2 Suspended
15 enrolled
PancFORT
Phase 2 Suspended
100 enrolled
HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma
Phase 2 Suspended
3 enrolled
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Phase 2 Suspended
120 enrolled
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
Phase 2 Suspended
100 enrolled
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
Phase 2 Suspended
68 enrolled
Neoadjuvant T-VEC in High Risk Early Melanoma
Phase 2 Suspended
6 enrolled